No Data
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Insiders Who Sold Pyxis Oncology Made The Right Call As Market Cap Slides By US$50m
No Data
No Data
